Parenteral Drugs (India) Limited reported unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2019. For the quarter, on a standalone basis, the company reported revenue from operations of INR 73.431 million compared to INR 88.949 million a year ago. Loss for the period was INR 283.139 million compared to loss for the year of INR 268.597 million a year ago. Basic and diluted loss per share was INR 9.50 compared to loss per share of INR 9.01 a year ago. For the half year, on a standalone basis, the company reported revenue from operations of INR 160.591 million compared to INR 194.581 million a year ago. Loss for the year was INR 560.0 million compared to INR 507.00 million a year ago. Basic and diluted loss per share was INR 18.79 compared to loss per share of INR 17.01 a year ago. For the quarter, on a consolidated basis, the company reported revenue from operations of INR 73.431 million compared to INR 88.949 million a year ago. Loss for the period was INR 283.139 million compared to loss for the year of INR 268.597 million a year ago. Basic and diluted loss per share was INR 9.50 compared to loss per share of INR 9.01 a year ago. For the half year, on a consolidated basis, the company reported revenue from operations of INR 160.591 million compared to INR 194.581 million a year ago. Loss for the year was INR 560.0 million compared to INR 507.00 million a year ago. Basic and diluted loss per share was INR 18.79 compared to loss per share of INR 17.01 a year ago.